Exceptional responders of new drugs in clinical trials.
Decoder
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, March 24, 2015

When a clinical trial of a new drug fails because most patients don’t respond, progress can still be made by analyzing the tumors of the rare patients who benefit.

Pictured: Charles Sawyers
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, March 12, 2015

Physician-scientist Charles Sawyers played a pivotal role in the development of Gleevec, one of the first successful targeted drugs for cancer.

Christina Leslie and John Petrini
Announcement
By Jim Stallard, MA, Writer/Editor  |  Thursday, February 12, 2015

MSK’s Functional Genomics Initiative will enable basic scientists to take full advantage of the massive amount of data produced by tumor sequencing.

Fibrous extensions of a nerve cell (red) and an oligodendrocyte (green) growing on top of the nerve cell
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, February 5, 2015

In a recent study, Memorial Sloan Kettering scientists used stem-cell engineering to repair brain injuries in rats. The results raise hope for future therapies that could prevent or fix nerve damage in cancer patients who need brain radiation.

Pictured: Michael Zelefsky
In the Clinic
By Eva Kiesler, PhD and Jim Stallard, MA
Monday, February 2, 2015

Researchers call for intensified efforts to help men with prostate cancer quit smoking after a recent MSK study revealed that patients who smoke during radiation therapy face a higher risk of both having the disease return and dying from it.

Epigenetics
Q&A
By Eva Kiesler, PhD, Science Writer/Editor  |  Friday, January 30, 2015

An experimental drug for acute myelogenous leukemia might potentially help many more patients than previously thought by controlling epigenetic processes, according to a recent MSK study.

In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, January 28, 2015

An annual report from an influential cancer group highlights three MSK studies that have advanced cancer research.

Neurons created from embryonic stem cells
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, January 22, 2015

A new tool called optogenetics is revealing clues about the function of a promising experimental therapy derived from stem cells.

Sandra D’Angelo and Jedd Wolchok
In the Clinic
By Jim Stallard, MA, Writer/Editor  |  Tuesday, January 6, 2015

A new treatment for advanced melanoma is the latest promising advance in immunotherapy tested in large part by our scientists.

Stained pathology slides of a patient’s tumor (right) and of an organoid made from that tumor (left).
In the Lab
By Christina Pernambuco-Holsten, MA, Managing Web Editor  |  Tuesday, December 30, 2014

From tropical plants and 3-D snapshots of worms to tiny particles that light up tumors, here’s a glimpse at some of the fascinating work MSK researchers pursued in 2014 as part of our quest to advance cancer science.

Pictured: Eytan Stein
In the Clinic
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, December 11, 2014

An experimental drug for blood cancers with certain genetic mutations is showing promise in early-stage trials.

Pictured: Viviane Tabar
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 1, 2014

Investigators have created the first-ever genetically engineered model of cancer made from human embryonic stem cells in culture.

Michel Sadelain and Prasad Adusumilli
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Wednesday, November 19, 2014

A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.

(From left) MSK investigators Michael Berger, José Baselga, and Maurizio Scaltriti, and graduate student Pau Castel.
Finding
By Julie Grisham, MS, Science Writer/Editor  |  Monday, November 17, 2014

A study of one patient’s disease has clarified why tumors stop responding to a class of experimental drugs called PI3K inhibitors.

Pictured: William Lee, Chris Sander & Nils Weinhold
In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Thursday, November 13, 2014

In a study of patient tumor samples, researchers have found common mutations in parts of the genome that control gene regulation.

Center News

Stay Informed

Get the latest information about cancer care and research every month.